Xtandi
Blocks androgen receptors and inhibits androgen receptor signalling to slow prostate cancer growth and delay disease progression in adult men with prostate cancer.
- Category
- Prostate Health
- Active ingredient
- Enzalutamide
- Route
- Oral use
- Form
- Capsule, soft; Film-coated tablet
- Strengths
- 40mg
You will receive a quality generic equivalent of Xtandi, depending on stock.
Prescription and consultation requirements for Xtandi vary by destination and are determined by the fulfilment partner.
Xtandi details
- Conditions
- Treatment of Adult Men with High-risk Biochemical Recurrent Non-metastatic Hormone-sensitive Prostate Cancer as Monotherapy or in Combination with Androgen Deprivation Therapy, Who Are Unsuitable for Salvage Radiotherapy · Treatment of Adult Men with Metastatic Hormone-sensitive Prostate Cancer in Combination with Androgen Deprivation Therapy · Treatment of Adult Men with High-risk Non-metastatic Castration-resistant Prostate Cancer · Treatment of Adult Men with Metastatic Castration-resistant Prostate Cancer Who Are Asymptomatic or Mildly Symptomatic After Failure of Androgen Deprivation Therapy in Whom Chemotherapy Is Not Yet Clinically Indicated · Treatment of Adult Men with Metastatic Castration-resistant Prostate Cancer Whose Disease Has Progressed on or After Docetaxel Therapy
- Therapeutic class
- Hormone antagonists and related agents
- Pharmacological class
- Androgen receptor inhibitor
- Minor side effects
- fatigue; asthenia; hot flush; hypertension; falls; fracture
- Moderate side effects
- headache; dry skin; pruritus; muscle spasms; back pain; haematuria
- Dosage forms
- Capsule, soft; Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Originator
- Astellas Pharma Europe B.V.
- Storage instructions
- This medicinal product does not require any special storage conditions.
Contraindications
hypersensitivity to enzalutamide or any excipients; women who are or may become pregnant
Precautions and warnings
risk of seizure; consider discontinuation if seizure occurs; posterior reversible encephalopathy syndrome has been reported; discontinue if confirmed; concomitant use with strong CYP2C8 inhibitors should be avoided or enzalutamide dose should be reduced; caution with CYP3A4, CYP2C9 or CYP2C19 substrates with narrow therapeutic index; ischaemic heart disease has been reported; falls and fractures reported; risk factors such as osteoporosis should be assessed; hypertension has been reported; blood pressure should be monitored; not to be handled by women who are or may become pregnant
Serious side effects
seizure, requires immediate medical attention; posterior reversible encephalopathy syndrome, requires immediate medical attention; myocardial infarction, requires immediate medical attention; ischaemic heart disease, requires immediate medical attention; severe hypersensitivity reaction, requires immediate medical attention
Patient summary
Blocks androgen receptors and inhibits androgen receptor signalling to slow prostate cancer growth and delay disease progression in adult men with prostate cancer.
Mechanism of action
Xtandi contains enzalutamide, a medicine that blocks the action of male hormones called androgens, including testosterone. Prostate cancer cells need androgens to grow. Enzalutamide works at multiple steps in the androgen receptor signalling pathway by preventing androgens from attaching to their receptors on cancer cells and blocking the receptors from sending growth signals to the cell nucleus. This helps slow the growth of prostate cancer and delay the spread of the disease.
Drug interactions
strong CYP2C8 inhibitors; CYP3A4 inducers; CYP3A4 substrates with narrow therapeutic index; CYP2C9 substrates with narrow therapeutic index; CYP2C19 substrates with narrow therapeutic index; warfarin; clopidogrel
Age restrictions
Not for use in children and adolescents. Safety and efficacy have not been established in paediatric population.
Pregnancy and breastfeeding
Contraindicated in women who are or may become pregnant. Not indicated for use in women. May cause harm to the unborn child. Effective contraception required for male patients with female partners of childbearing potential.
What you will receive
Xtandi is the originator brand name, made by Astellas Pharma Europe B.V.. We use it to identify the medicine and are not affiliated with Astellas Pharma Europe B.V..
- The fulfilment partner confirms whether the exact brand or an equivalent containing Enzalutamide is offered.
- The offered brand, manufacturer and dispatch location depend on the product, destination and partner warehouse.
- Check the final product details at checkout before confirming an order.